Radiat Oncol J.
2017 Jun;35(2):121-128. 10.3857/roj.2017.00150.
In vivo dosimetry and acute toxicity in breast cancer patients undergoing intraoperative radiotherapy as boost
- Affiliations
-
- 1Department of Radiation Oncology, Yonsei University College of Medicine, Seoul, Korea. junwon@yuhs.ac
- 2Department of Surgery, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
- KMID: 2386209
- DOI: http://doi.org/10.3857/roj.2017.00150
Abstract
- PURPOSE
To report the results of a correlation analysis of skin dose assessed by in vivo dosimetry and the incidence of acute toxicity. This is a phase 2 trial evaluating the feasibility of intraoperative radiotherapy (IORT) as a boost for breast cancer patients.
MATERIALS AND METHODS
Eligible patients were treated with IORT of 20 Gy followed by whole breast irradiation (WBI) of 46 Gy. A total of 55 patients with a minimum follow-up of 1 month after WBI were evaluated. Optically stimulated luminescence dosimeter (OSLD) detected radiation dose delivered to the skin during IORT. Acute toxicity was recorded according to the Common Terminology Criteria for Adverse Events v4.0. Clinical parameters were correlated with seroma formation and maximum skin dose.
RESULTS
Median follow-up after IORT was 25.9 weeks (range, 12.7 to 50.3 weeks). Prior to WBI, only one patient developed acute toxicity. Following WBI, 30 patients experienced grade 1 skin toxicity and three patients had grade 2 skin toxicity. Skin dose during IORT exceeded 5 Gy in two patients: with grade 2 complications around the surgical scar in one patient who received 8.42 Gy. Breast volume on preoperative images (p = 0.001), ratio of applicator diameter and breast volume (p = 0.002), and distance between skin and tumor (p = 0.003) showed significant correlations with maximum skin dose.
CONCLUSIONS
IORT as a boost was well-tolerated among Korean women without severe acute complication. In vivo dosimetry with OSLD can help ensure safe delivery of IORT as a boost.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Feasibility of Intraoperative Radiotherapy Tumor Bed Boost in Patients with Breast Cancer after Neoadjuvant Chemotherapy
- Toxicity of Tomotherapy-Based Simultaneous Integrated Boost in Whole-Pelvis Radiation for Prostate Cancer
- Development of Dose Verification Method for In vivo Dosimetry in External Radiotherapy
- A comparison between high dose rate brachytherapy and stereotactic body radiotherapy boost after elective pelvic irradiation for high and very high-risk prostate cancer
- Clinical factors affecting the determination of radiotherapy-induced skin toxicity in breast cancer
